Mide Dışı Gastrointestinal Stromal Tümörlerin Yönetimi
Referanslar
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S. vd. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279(5350), 577-580. https://doi.org/10.1126/science.279.5350.577
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N. vd. (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299(5607), 708-710. https://doi.org/10.1126/science.1079666
Serrano, C., Martín-Broto, J., Asencio-Pascual, J. M., López-Guerrero, J. A., Rubió-Casadevall, J., Bagué, S. vd. (2023). 2023 GEIS Guidelines for gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 15, 17588359231192388. https://doi.org/10.1177/17588359231192388
Miettinen, M. ve Lasota, J. (2006). Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Seminars in Diagnostic Pathology, 23(2), 70-83. https://doi.org/10.1053/j.semdp.2006.09.001
Joensuu, H., Vehtari, A., Riihimäki, J., Nishida, T., Steigen, S. E., Brabec, P. vd. (2012). Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts. The Lancet Oncology, 13(3), 265-274. https://doi.org/10.1016/S1470-2045(11)70299-6
Reith, J. D., Goldblum, J. R., Lyles, R. H. ve Weiss, S. W. (2000). Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. Modern Pathology, 13(5), 577-585. https://doi.org/10.1038/modpathol.3880099
Agaimy, A. ve Wünsch, P. H. (2006). Gastrointestinal stromal tumours: A regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbeck's Archives of Surgery, 391(4), 322-329. https://doi.org/10.1007/s00423-005-0005-5
Casali, P. G., Blay, J.-Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R. vd. (2022). Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 33(1), 20-33. https://doi.org/10.1016/j.annonc.2021.09.005
Hirota, S., Tateishi, U., Nakamoto, Y., Nishida, T., Okubo, K., Yamaguchi, U. vd. (2024). English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. International Journal of Clinical Oncology, 29, 647-680. https://doi.org/10.1007/s10147-024-02488-1
Judson, I., Jones, R. L., Wong, N. A. C. S., Dileo, P., Bulusu, R., Smith, M. ve Almond, M. (2025). Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines. British Journal of Cancer, 132(1), 1-10. https://doi.org/10.1038/s41416-024-02672-0
Hirano, H., Naito, Y., Takahashi, T., Hirota, S., Kim, K.-M., Ryu, M.-H. vd. (2026). Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025). Gastric Cancer, 29, 887-903. https://doi.org/10.1007/s10120-026-01773-4
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J. vd. (2002). Diagnosis of gastrointestinal stromal tumors: A consensus approach. Human Pathology, 33(5), 459-465. https://doi.org/10.1053/hupa.2002.123545
Liegl, B., Hornick, J. L., Corless, C. L. ve Fletcher, C. D. M. (2009). Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. American Journal of Surgical Pathology, 33(3), 437-446. https://doi.org/10.1097/PAS.0b013e318186b158
Lin, J., Liao, W., Wang, J., Li, W., Tang, X., Li, H. vd. (2023). Primary extra-gastrointestinal stromal tumor of retroperitoneum: Clinicopathologic characteristics and prognosis of six cases. Frontiers in Oncology, 13, 1033598. https://doi.org/10.3389/fonc.2023.1033598
Wang, S., Sun, F. ve Wang, X. (2025). Domestic research on extra-gastrointestinal stromal tumors: A ten-year review. Journal of Central South University. Medical Sciences, 50(2), 237-250. https://doi.org/10.11817/j.issn.1672-7347.2025.240044
Søreide, K., Sandvik, O. M., Søreide, J. A., Giljaca, V., Jureckova, A. ve Bulusu, V. R. (2016). Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiology, 40, 39-46. https://doi.org/10.1016/j.canep.2015.10.031
Miettinen, M., Kopczynski, J., Makhlouf, H. R., Sarlomo-Rikala, M., Gyorffy, H., Burke, A. vd. (2003). Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: A clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. American Journal of Surgical Pathology, 27(5), 625-641. https://doi.org/10.1097/00000478-200305000-00006
Miettinen, M., Makhlouf, H., Sobin, L. H. ve Lasota, J. (2006). Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. American Journal of Surgical Pathology, 30(4), 477-489. https://doi.org/10.1097/00000478-200604000-00008
Miettinen, M., Sarlomo-Rikala, M., Sobin, L. H. ve Lasota, J. (2000). Gastrointestinal stromal tumors and leiomyosarcomas in the colon: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. American Journal of Surgical Pathology, 24(10), 1339-1352. https://doi.org/10.1097/00000478-200010000-00003
Miettinen, M. ve Sobin, L. H. (2001). Gastrointestinal stromal tumors in the appendix: A clinicopathologic and immunohistochemical study of four cases. American Journal of Surgical Pathology, 25(11), 1433-1437. https://doi.org/10.1097/00000478-200111000-00013
Miettinen, M., Furlong, M., Sarlomo-Rikala, M., Burke, A., Sobin, L. H. ve Lasota, J. (2001). Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. American Journal of Surgical Pathology, 25(9), 1121-1133. https://doi.org/10.1097/00000478-200109000-00002
Joensuu, H. (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathology, 39(10), 1411-1419. https://doi.org/10.1016/j.humpath.2008.06.025
D’Ambrosio, L., Fumagalli, E., Martino De Pas, T., Nannini, M., Bertuzzi, A., Carpano, S. vd. (2023). Guideline-based follow-up outcomes in patients with gastrointestinal stromal tumor with low risk of recurrence: A report from the Italian Sarcoma Group. JAMA Network Open, 6(11), e2341522. https://doi.org/10.1001/jamanetworkopen.2023.41522
Nishida, T., Hølmebakk, T., Raut, C. P. ve Rutkowski, P. (2019). Defining tumor rupture in gastrointestinal stromal tumor. Annals of Surgical Oncology, 26(6), 1669-1675. https://doi.org/10.1245/s10434-019-07297-9
McCarter, M. D., Antonescu, C. R., Ballman, K. V., Maki, R. G., Pisters, P. W. T., Demetri, G. D. vd. (2012). Microscopically positive margins for primary gastrointestinal stromal tumors: Analysis of risk factors and tumor recurrence. Journal of the American College of Surgeons, 215(1), 53-59. https://doi.org/10.1016/j.jamcollsurg.2012.05.008
Hølmebakk, T., Bjerkehagen, B., Hompland, I., Stoldt, S. ve Boye, K. (2019). Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour. British Journal of Surgery, 106(4), 419-426. https://doi.org/10.1002/bjs.11027
Robb, W. B., Bruyère, E., Amielh, D., Vinatier, E., Mabrut, J.-Y., Perniceni, T. vd. (2015). Esophageal gastrointestinal stromal tumor: Is tumoral enucleation a viable therapeutic option? Annals of Surgery, 261(1), 117-124. https://doi.org/10.1097/SLA.0000000000000505
Mohammadi, M., IJzerman, N. S., Hohenberger, P., Rutkowski, P., Jones, R. L., Gronchi, A. vd. (2021). Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. European Journal of Surgical Oncology, 47(8), 2173-2181. https://doi.org/10.1016/j.ejso.2021.03.234
Zhu, S., Guo, C., Zhang, J., Dai, N., Ullah, S., Liu, P., Fu, Y., Zhang, G., Zhang, F., Zhang, S. ve Cao, X. (2024). Optimal management options for esophageal gastrointestinal stromal tumors (E-GIST). European Journal of Surgical Oncology, 50(9), 108527. https://doi.org/10.1016/j.ejso.2024.108527
Zhou, Y., Peng, R., Chen, X., Xie, X., Chen, J. ve Li, R. (2025). The feasibility of endoscopic resection for esophageal gastrointestinal stromal tumor. Surgical Endoscopy, 39(6), 3718-3726. https://doi.org/10.1007/s00464-025-11763-9
Li, T. M., Kouanda, A. ve Adam, M. A. (2026). Defining the role of endoscopic resection for esophageal gastrointestinal stromal tumors. Journal of Gastrointestinal Oncology, 17(3), 188. https://doi.org/10.21037/jgo-2026-0205
Chok, A. Y., Koh, Y. X., Ow, M. Y. L., Allen, J. C. Jr. ve Goh, B. K. P. (2014). A systematic review and meta-analysis comparing pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors. Annals of Surgical Oncology, 21(11), 3429-3438. https://doi.org/10.1245/s10434-014-3788-1
Lee, S. Y., Goh, B. K. P., Sadot, E., Rajeev, R., Balachandran, V. P., Gönen, M. vd. (2017). Surgical strategy and outcomes in duodenal gastrointestinal stromal tumor. Annals of Surgical Oncology, 24(1), 202-210. https://doi.org/10.1245/s10434-016-5565-9
Wu, L., Liu, M., Lin, X., Wang, C., Yang, Y., Fang, H. vd. (2024). Feasibility and efficacy of minimally invasive limited resection for primary duodenal gastrointestinal stromal tumors: A retrospective cohort study. BMC Surgery, 24, 126. https://doi.org/10.1186/s12893-024-02417-z
Sun, Y., Li, J., Wu, D., Tian, Y., Wang, R., Kuang, T. vd. (2025). The feasibility and safety of laparoscopic limited resection for duodenal gastrointestinal stromal tumor: A propensity score-matched analysis. Surgical Endoscopy, 39(12), 8064-8072. https://doi.org/10.1007/s00464-025-12088-3
Cavnar, M. J., Wang, L., Balachandran, V. P., Antonescu, C. R., Tap, W. D., Keohan, M. vd. (2017). Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: Organ preservation and improved oncologic outcome. Annals of Surgical Oncology, 24(13), 3972-3980. https://doi.org/10.1245/s10434-017-6087-9
Yang, W., Liu, Q., Lin, G., Zhang, B., Cao, H., Zhao, Y. vd. (2021). The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study. Journal of Surgical Oncology, 124(7), 1128-1135. https://doi.org/10.1002/jso.26628
Lam, T. J. R., Udonwa, S. A., Masuda, Y., Yeo, M. H. X., Farid Bin Harunal Ras, M. ve Goh, B. K. P. (2024). A systematic review and meta-analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors. World Journal of Surgery, 48(7), 1681-1691. https://doi.org/10.1002/wjs.12210
Chen, J.-H., Cai, Z.-M., Yang, Z.-R., Lin, T., Hong, S.-C., Su, X.-C., Lin, Y.-M., Lin, L., Ye, Z.-S. ve Zhou, Y.-J. (2026). Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: A two-center retrospective cohort study. BMC Gastroenterology, 26(1), 8. https://doi.org/10.1186/s12876-025-04467-w
Khan, S. I., O’Sullivan, N. J., Temperley, H. C., Rausa, E., Mehigan, B. J., McCormick, P., Larkin, J. O., Kavanagh, D. O. ve Kelly, M. E. (2023). Gastrointestinal stromal tumours (GIST) of the rectum: A systematic review and meta-analysis. Current Oncology, 30(1), 416-429. https://doi.org/10.3390/curroncol30010034
Wang, D., Zhang, Q., Blanke, C. D., Demetri, G. D., Heinrich, M. C., Watson, J. C. vd. (2012). Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology, 19(4), 1074-1080. https://doi.org/10.1245/s10434-011-2190-5
Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hermes, B., Schütte, J. vd. (2020). Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: An analysis of a randomized clinical trial after 10-year follow-up. JAMA Oncology, 6(8), 1241-1246. https://doi.org/10.1001/jamaoncol.2020.2091
Blay, J.-Y., Schiffler, C., Bouché, O., Brahmi, M., Duffaud, F., Toulmonde, M. vd. (2024). A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Annals of Oncology, 35(12), 1157-1168. https://doi.org/10.1016/j.annonc.2024.08.2343
Ford, S. J. ve Gronchi, A. (2016). Indications for surgery in advanced/metastatic GIST. European Journal of Cancer, 63, 154-167. https://doi.org/10.1016/j.ejca.2016.05.019